TABLE 3.

Summary of ARV drug concentrations in CVF, CVL, and VT^a

Analyte, matrix	n	LLQ	% >LLQb	Median (IQR)c
TDF, CVF	56	1.5 ng ml−1d	39	26 (17–43)e; 36 (21–53)f
TFV, CVF	56	5 ng ml−1d	98	5.6 × 103 (3.1 × 103–8.6 × 103)e; 4.4 × 103 (3.3 × 103–9.1 × 103)f
MVC, CVF	56	8 ng ml−1d	100	1.4 × 104 (5.6 × 103–3.3 × 104)e; 1.5 × 104 (5.5 × 103–3.9 × 104)f
TDF, CVL	28	0.5 ng ml−1g	96	42 (27–64)h
TFV, CVL	28	5 ng ml−1g	100	8.4 × 103 (3.6 × 103–2.2 × 104)h
MVC, CVL	28	8 ng ml−1g	100	2.4 × 104 (1.3 × 104–4.7 × 104)h
TFV, VT	8	0.05 ng g−1	100	7.3 × 102 (3.0 × 102–4.0 × 103)
TFV-DP, VT	8	50 fmol g−1i	88	1.8 × 104 (1.5 × 104–4.8 × 104)
MVC, VT	8	0.05 ng g−1	100	8.2 × 102 (4.7 × 102–2.0 × 103)
TFV, plasma	36	2 ng ml−1	0	BLQj
MVC, plasma	36	3 ng ml−1	0	BLQ

^aAll values correspond to time points with IVR in place (n = 4).

^bData represent proportions of samples that contained quantifiable drug levels.

^cInterquartile range (25th to 75th percentile).

^dData represent nanograms per sample.

^eSample collected from the midvagina, ventral.

^fSample collected from the midvagina, dorsal.

^gData represent CVL fluid uncorrected for CVF dilution.

^hData correspond to drug levels in CVF compensated for dilution during the CVL procedure.

ⁱData represent femtomoles per sample.

^jBLQ, below LLQ.